Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series) - Image 1

£75.00

CRC Press Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)

Name: Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)
Brand: CRC Press
Price: 75.0 GBP
Availability: InStock

General Medical Issues

Price History & Forecast

Last 34 days • 34 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 34 days • 1 price levels

Days at Price

Price Analysis

Most common price: £75 (34 days, 100.0%)

Price range: £75 - £75

Price levels: 1 different prices over 34 days

Description

Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment. The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule’s journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies. The book also focuses on a molecule’s entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety. Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.

Key Features

Used Book in Good Condition

Product Specifications

Brand: CRC Press
Format: Hardcover
ASIN: 1439867941
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > General Medical Issues
Domain: Amazon UK
Release Date: 27 November 2013
Listed Since: 13 February 2012

Barcode

No barcode data available

CRC Press Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)

Price History & Forecast

Price Distribution

Price Analysis

Description

Key Features

Product Specifications

Barcode

Similar Products You Might Like

Statistics In the Pharmaceutical Industry: 14 (Chapman & Hall/CRC Biostatistics Series)

The Benefit/Risk Ratio: A Handbook for the Rational Use of Potentially Hazardous Drugs

Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting (Chapman & Hall/CRC Biostatistics Series)

Bayesian Methods in Pharmaceutical Research (Chapman & Hall/CRC Biostatistics Series)

Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman & Hall/CRC Biostatistics Series)

CRC Press Bayesian Methods in Pharmaceutical Research Book

Innovative Statistics in Regulatory Science (Chapman & Hall/CRC Biostatistics Series)

Case Studies in Innovative Clinical Trials (Chapman & Hall/CRC Biostatistics Series)

Multiregional Clinical Trials for Simultaneous Global New Drug Development (Chapman & Hall/CRC Biostatistics Series)

Biomarker Analysis in Clinical Trials with R (Chapman & Hall/CRC Biostatistics Series)

Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series)

Biomarker Analysis in Clinical Trials with R (Chapman & Hall/CRC Biostatistics Series)

Development and Evaluation of Drugs: From Laboratory through Licensure to Market

Re-inventing Drug Development - CRC Press Biopharma Book

Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting: 67 (Chapman & Hall/CRC Biostatistics Series)

Quantitative Drug Safety and Benefit Risk Evaluation: Practical and Cross-Disciplinary Approaches (Chapman & Hall/CRC Biostatistics Series)

Project Management for Drug Developers (Drugs and the Pharmaceutical Sciences)

Multiregional Clinical Trials for Simultaneous Global New Drug Development (Chapman & Hall/CRC Biostatistics Series)

Real-World Evidence in Drug Development and Evaluation (Chapman & Hall/CRC Biostatistics Series)

Multiple Testing Problems in Pharmaceutical Statistics: 33 (Chapman & Hall/CRC Biostatistics Series)

Innovative Methods for Rare Disease Drug Development (Chapman & Hall/CRC Biostatistics Series)

Clinical and Statistical Considerations in Personalized Medicine (Chapman & Hall/CRC Biostatistics)

Multiple Testing Problems in Pharmaceutical Statistics (Chapman & Hall/CRC Biostatistics Series)

Real-World Evidence in Drug Development and Evaluation (Chapman & Hall/CRC Biostatistics Series)